Thursday July 2, 2009

4.30 PM                     Departure from Hotel Residence (by bus)

4.45 PM                     Arrival at La Villa - Aperitif

5.15–5.30                 Opening remarks

                             K.-W. Jauch, Munich

5.30-6.15                  Keynote lecture

Using chemokines to direct leukocyte traffic and impact on cancer therapy

F. Sallusto, Bellinzona, Switzerland

6.30                           Dinner

---

Friday July 3, 2009

 

8:00-9:45                  Session 1: Manipulating the (tumor) microenvironment to improve immunotherapeutic treatment strategies

Co-Chairs:     Ch. Huber, Mainz – H. Winter, Munich

 

8:05-8:30                  Manipulating regulatory T-cells to enhance anti-tumor

•       immunity

B.A. Fox, Portland, OR

8:30-8:55                  DAMPs and redox: Role in inflammation and cancer

M. Lotze, Pittsburgh, PA

 

8:55-9:20                  Biologic effects of vaccine adjuvants systemically and at the site of multipeptide vaccines

C. Slingluff Jr., Charlottesville, VA

9:20-9:45                  Mechanism of synergistic effect of chemotherapy and 

                             cancer vaccines

D. Gabrilovich, Tampa, FL

9:45-10:15            Coffee break

 

10:15-12.45             Session 2: Will there be a role for vaccines in anti-cancer therapy?

Co-Chairs: L.A. Emens, Baltimore, MD – J. Weber, Tampa,

FL

 

10:15-10:40             Multiple peptide vaccines in early melanoma and prostate

    carcinoma

L. Rivoltini, Milan, Italy

10:40-11:05             Exploiting autophagy: cross-priming of tumor-specific T cells against short-lived proteins

W. J. Urba, Portland, OR

11:30-11:55             Can chemotherapy be successfully combined with cancer

                            vaccines?

L.A. Emens, Baltimore, MD

11:55-12:20              Drawbacks in cancer vaccines: Overcoming tolerance by exploiting immune regulatory molecules

J. Weber, Tampa, FL

 

12:20-12:45           Roundtable discussion: Lessons learned from developing anti-cancer vaccines

L.A. Emens, S. Endres, B.A. Fox, S. Khlief, M. Lotze, L. Rivoltini, C. Slingluff Jr., W.J. Urba, J. Weber

 

12:45-2:15               Lunch

 

2:15-3:30                  Session 3: Designing optimal combinations for

                                   immunotherapy

Co-Chairs: J. Becker, Würzburg – D. Rüttinger, Munich

 

2:15-2:40                 OX40 costimulation as a therapeutic strategy for cancer immunotherapy: Preclinical and clinical results

A. Weinberg, Portland, OR

2:40-3:05                  Drawbacks in cancer vaccines: Overcoming tolerance by exploiting immune regulatory molecules

J. Weber, Tampa, FL

2:40-3:05                  Use of novel markers and chemokines for immunotherapy

J. Mulé, Tampa, FL

3:05-3:30                  RNA oligonucleotides for immunotherapy of cancer

S. Endres, Munich

 

3:30-4:00                  Coffee break

 

4:00-5:15                  Session 4: Optimizing adoptive cell therapy

Co-Chairs: R. Morgan, Bethesda, MD – D.J. Schendel,       

Munich

 

4:00-4:25                  Selecting high-affinity T cells for adoptive T cell therapy

D.J. Schendel, Munich

4:25-4:50                  HER2-reactive T cells for adoptive transfer in breast

                             cancer

H. Bernhard, Darmstadt

4:50-5:15                  Genetically modified T cells for adoptive transfer

R. Morgan, Bethesda, MD

 

 

7 PM                           Dinner

---

Saturday July 4, 2009

 

9:00-10:00                Poster presentations/Poster Awardee Selection

Co-Chairs: M. Lotze, R.K. Puri, C. Slingluff Jr,

W. Zimmermann

 

10:00-10:50             Session 5: Targeted and novel immunotherapeutic

                                   approaches

Co-Chairs: Ch. Itin, Munich – W. Urba, Portland, OR

 

10:00-10:25             Blinatumomab, a T-cell engaging bispecific antibody for the treatment of NHL

Ch. Itin, Munich

10:25-10:50             Catumaxomab (Removab): The road from preclinical development to approval

D. Seimetz, Munich

 

10:50-11:20             Coffee break

 

11:20-12:10             Session 5: continued

11:20-11:45             Targeting IL-13Ra2 for cancer therapy

R.K. Puri, Bethesda, MD

11:45-12:10             Melanoma stem cells: targets for immunotherapy?

J. Becker, Würzburg

 

12:10-1:45               Lunch

 

1:45-3:25                  Session 6: Improving immunotherapeutic approaches

                                    Co-Chairs: L. Zitvogel, Villejuif, France – S. Khleif, Bethesda, MD

 

1:45-2:10              The value of adding T help to clinical vaccine approaches

S. Khleif, Bethesda, MD

 

2:10-2:35              MAGE-A3 cancer immunotherapeutics in metastatic

                            melanoma

J.F. Baurain, Brussels, Belgium

2:35-3:00                  Molecular pathways involved in the immunogenicity of chemotherapy in cancer

L. Zitvogel, Villejuif, France

3:00-3:25               Combining anti-tumor mAB and inibs: where are we and where are we heading for

R. Huber, Munich

 

3:25-4:00                  Coffee break

 

4:00-5:00                  Round table discussion: Overcoming obstacles to approval of combination biologics

Moderators: J. Weber, Tampa, FL - B.A. Fox, Portland OR

 

Regulatory issues for combination therapies (the US perspective)

R.K. Puri, Bethesda, MD

Regulatory issues for combination therapies (the EU perspective)

T. Hinz, Langen

 

5:00-5:15                  Poster prize and closing remarks

                            J. Weber, Tampa, FL - B.A. Fox, Portland OR

The “Asklepios Poster Prize 2009 for innovative cancer therapy“ will be awarded to the winner by Prof. R.A. Hatz